|
Press Release: Phase I Clinical Trials comes to Wasatch Front
May 15th, 2008 Orem, Utah: Aspen Clinical Research, LLC a Utah corporation announces the opening of it’s 20,000 sq ft. state of the art 50 bed inpatient research facility. Phase I clinical trials encompasses first in human safety studies as a part of ongoing research into the treatment of medical conditions. Aspen Clinical Research has been participating in Phase II-IV studies previously, but now adds the Phase I studies to their scope of research services. Dr. Michael W. Harris, Chief Medical Officer states “Clinical Research is the backbone of our medical community, leading edge technology and ongoing research gives us real hope in finding cures for those illnesses that affect our families and loved ones.” The facility is scheduled to open in the third quarter of this year.
Press Release: Dr. Michael W. Harris to Present Vyvance Indications for Shire
May 10th 2008 Orem, Utah: Dr Michael W. Harris, Chief Medical Officer over clinical trials for Aspen Clinical Research will be presenting at the Chicago Mental Health Coalition next week about preferred clinical protocols in prescribing Vyvance for the indicated treatment of ADD. Dr. Harris was the founder of the Utah Attention Deficit Center in Provo, Utah and has been actively involved in the study and treatment of ADD and ADHD in correlation to several other mental and physical health.
Press Release: Dr. Michael W. Harris keynote speaker at Kansas City Mental Health Conference.
December 4th, 2007, Kansas City, Missouri: Dr Michael W. Harris, Chief Medical Officer over clinical trials for Aspen Clinical Research will be the keynote speaker for Sanofi-Aventis regarding new indications treated with Ambien CR relating to ADD related Insomnia. Dr. Harris was the founder of the Utah Attention Deficit Center in Provo, Utah and has been actively involved in the study and treatment of ADD and ADHD in correlation to several other mental and physical health.
Press Release: Dr. Michael W. Harris to Present at California ADD Conference
August 24th, 2007 Los Angeles, California: Dr Michael W. Harris, Chief Medical Officer over clinical trials for Aspen Clinical Research, will be presenting at the California ADD conference regarding Adderal XR Indications for Shire Pharmaceuticals. Dr. Harris was the founder of the Utah Attention Deficit Center in Provo, Utah and has been actively involved in the study and treatment of ADD and ADHD in correlation to several other mental and physical health.
Press Release: Aspen Clinical Research names Michael W. Harris D.O. as Chief Medical Officer.
August 4th, 2007 Orem, Utah: Aspen Clinical Research, LLC a Utah corporation named Dr. Michael W. Harris as their Chief Medical Director over clinical trials. Dr. Harris has over 15 years of clinical practice experience in Mental Health and Central Nervous System treatment. Dr. Harris was the founder of the Utah Attention Deficit Center and has also been the Medical Director for the Intermountain Sleep Clinics, Utah Wellness Center, CTH Hospice Care, and several other mental health programs. Dr. Harris graduated from the University of Missouri – Columbia. Dr Harris is also a reputable Physician speaker for several pharmaceutical companies.
Press Release: Dr. Michael W. Harris to Present Lunesta Indications for Sepracor
June 19th, 2007 Salt Lake City, Utah: Dr Michael W. Harris, Chief Medical Officer over clinical trials for Aspen Clinical Research will be presenting at the American Sleep Association in behalf of Sepracor Pharmaceuticals for their sleep medication Lunesta. Dr. Harris, formerly was the acting Medical Director for the Intermountain Sleep Clinics.
Press Release: Dr. Michael W. Harris to Present Lexapro Indications for Forest
February 10th, 2007 Las Vegas, Nevada: Dr Michael W. Harris, Founder of the Utah Attention Deficit Center will address healthcare professionals at the Association of Clinical Depression (ACD) for Forest pharmaceuticals in regards to the prescribing indications with Lexapro. Dr. Harris an expert in the field of Clinical Depression treatment is featured as one of three keynote speakers.
Press Release: Dr. Michael W. Harris to Present Geodon Indications for Pfizer
November 16th, 2006 Phoenix, Arizona: Dr Michael W. Harris, Founder of the Utah Attention Deficit Center will address healthcare professionals at the Arizona Mental Health Convention as a keynote speaker for Pfizer Pharmaceuticals. Dr. Harris will discuss the indications and usage of Geodon in the clinical treatment of Bipolar Disorder.
Dr. Harris is currently serving as Medical Director for Utah Wellness Center in the treatment of CNS associated conditions.
|
